New tools for more precise drug delivery systems
Kimbelery Pardo – Marketing and Business Development Analyst
The pharmaceutical industry is undergoing a period of profound transformation driven by the convergence of materials science, biology, and technology. In this context, smart biomaterials and nanotechnology are emerging as key tools for the development of more precise and controllable drug delivery systems.
Recently, an Indo-ASEAN international seminar brought together researchers, clinical professionals, and industry experts to analyze advances in this field. The discussion focused on materials capable of actively responding to the biological environment, a characteristic that is redefining the traditional concept of drug delivery.
What are smart biomaterials?
Smart biomaterials are designed to modify their behavior in response to specific stimuli, such as:
- changes in pH,
- temperature,
- the presence of specific biomolecules.
When integrated with nanotechnology, these materials can modulate drug release, improve interaction with tissues, and enhance overall system stability.
Impact on pharmaceutical development
The advances presented highlight tangible benefits for the industry:
- Greater control over release profiles, reducing unwanted peaks.
- Improved performance in complex formulations, particularly in sustained-release therapies.
- Reduced variability, a critical factor in regulated environments.
From a manufacturing perspective, these systems enable more robust processes aligned with Quality by Design (QbD) principles.
Relevance for transdermal systems
From a transdermal perspective, smart biomaterials offer opportunities to:
- improve patch–skin interaction,
- optimize the permeation of complex APIs,
- design systems that are more adaptable to real-world use conditions.
Nanotechnology, in turn, provides control over particle size, shape, and functionalization—key variables for achieving consistency and reproducibility.
Challenges and next steps
While the potential is significant, challenges remain related to:
- industrial scalability,
- regulatory validation,
- integration with existing platforms.
However, the growing dialogue between research, clinical practice, and industry is accelerating the maturation of these technologies. As they continue to evolve, smart biomaterials are expected to move beyond promise and become a standard component of advanced pharmaceutical development.
